Table 3.
Competing choice cost-effectiveness analysis for Delhi and Gujarat
| Scenario | Total costs (USD, 1000s) | Total DALYs averted (1000s) | Incremental cost (USD, 1000s) | Incremental DALYs averted (1000s) | Cost (USD) per DALY averted |
|---|---|---|---|---|---|
| Delhi | |||||
| M72/AS01E policy scenarios | |||||
| No-new-vaccine | 977,788 | — | — | — | — |
| Basecase (routine age 15, campaign for ages 16–34) | 982,966 | 1,465 | 5,178 | 1,465 | 4 |
| Older ages (routine age 17, campaign for ages 18–55) | 1,023,279 | 1,786 | 40,313 | 321 | 126 |
| All-adults (routine age 18, campaign for ages 19+) | 1,050,875 | 1,873 | 27,596 | 87 | 317 |
| BCG-revaccination policy scenarios | |||||
| No-new-vaccine | 977,788 | — | — | — | — |
| Basecase (routine age 10, campaign for ages 11–18) | 940,220 | 938 | −37,568 | 938 | Cost-saving |
| Older ages (routine age 15, campaign for ages 16–34) | 973,930 | 693 | — | — | Strongly dominated |
| All-Adults (routine age 18, campaign for ages 19+) | 1,032,616 | 521 | — | — | Strongly dominated |
| Gujarat | |||||
| M72/AS01E policy scenarios | |||||
| No-new-vaccine | 584,609 | — | — | — | — |
| Basecase (routine age 15, campaign for ages 16–34) | 917,077 | 308 | — | — | Weakly dominated |
| Older ages (routine age 17 campaign for ages 18–55) | 1,097,770 | 505 | — | — | Weakly dominated |
| All-Adults (routine age 18, campaign for ages 19+) | 1,208,573 | 640 | 623,965 | 640 | 975 |
| BCG-revaccination policy scenarios | |||||
| No-New-Vaccine | 584,609 | — | — | — | — |
| Basecase (routine age 10, campaign for ages 11–18) | 661,265 | 219 | 76,656 | 219 | 351 |
| Older ages (routine age 15, campaign ages 16–34) | 708,672 | 273 | 47,407 | 55 | 868 |
| All-Adults (routine age 18, campaign ages 19+) | 844,338 | 312 | 135,666 | 39 | 3,486 |